Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Total Liabilities: 2009-2025

Historic Total Liabilities for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $191.9 million.

  • Lifecore Biomedical's Total Liabilities fell 4.07% to $191.9 million in Q2 2025 from the same period last year, while for May 2025 it was $191.9 million, marking a year-over-year decrease of 4.07%. This contributed to the annual value of $191.9 million for FY2025, which is 4.07% down from last year.
  • Latest data reveals that Lifecore Biomedical reported Total Liabilities of $191.9 million as of Q2 2025, which was up 0.86% from $190.3 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Total Liabilities ranged from a high of $304.7 million in Q1 2021 and a low of $163.1 million during Q1 2023.
  • Moreover, its 3-year median value for Total Liabilities was $197.8 million (2024), whereas its average is $197.6 million.
  • In the last 5 years, Lifecore Biomedical's Total Liabilities plummeted by 40.36% in 2022 and then rose by 16.90% in 2023.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Total Liabilities stood at $265.9 million in 2021, then dropped by 22.96% to $204.8 million in 2022, then fell by 0.66% to $203.5 million in 2023, then dropped by 3.86% to $195.6 million in 2024, then decreased by 4.07% to $191.9 million in 2025.
  • Its last three reported values are $191.9 million in Q2 2025, $190.3 million for Q1 2025, and $195.6 million during Q4 2024.